Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Mack

Showing results (261-270 of 444) with videos related to

Pageof 45
Sort By:
Journal of Neurosurgery|January 14, 2015
ResponseGelareh Zadeh, Sameer Agnihotri, Isabel Gugel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003Philip C Mack, Mary W Redman, Kari Chansky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology GroupChristopher W Ryan, Bryan H Goldman, Primo N Lara, et al.
Cancer Research|December 1, 1995
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expressionS J DeNardo, P H Gumerlock, M D Winthrop, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2Paul J Hesketh, Kari Chansky, Antoinette J Wozniak, et al.
Cancer|April 23, 2014
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)Gerold Bepler, Ralph G Zinner, James Moon, et al.
Clinical Lung Cancer|November 10, 2021
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLCFred R Hirsch, Mary W Redman, James Moon, et al.
Cancer Letters|April 24, 2007
Origin and prognostic value of circulating KRAS mutations in lung cancer patientsO Gautschi, B Huegli, A Ziegler, et al.
Journal of Clinical and Experimental Neuropsychology|June 11, 2009
Persistent neuropsychological impairment associated with West Nile virus infectionJoseph R Sadek, Steven A Pergam, Jennifer A Harrington, et al.
Nature|July 22, 2014
A shift of thermokarst lakes from carbon sources to sinks during the Holocene epochK M Walter Anthony, S A Zimov, G Grosse, et al.
Pageof 45

Showing results (261-270 of 444) with videos related to

Sort By:
Pageof 45
Journal of Neurosurgery|January 14, 2015
ResponseGelareh Zadeh, Sameer Agnihotri, Isabel Gugel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003Philip C Mack, Mary W Redman, Kari Chansky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology GroupChristopher W Ryan, Bryan H Goldman, Primo N Lara, et al.
Cancer Research|December 1, 1995
Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expressionS J DeNardo, P H Gumerlock, M D Winthrop, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2Paul J Hesketh, Kari Chansky, Antoinette J Wozniak, et al.
Cancer|April 23, 2014
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)Gerold Bepler, Ralph G Zinner, James Moon, et al.
Clinical Lung Cancer|November 10, 2021
EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLCFred R Hirsch, Mary W Redman, James Moon, et al.
Cancer Letters|April 24, 2007
Origin and prognostic value of circulating KRAS mutations in lung cancer patientsO Gautschi, B Huegli, A Ziegler, et al.
Journal of Clinical and Experimental Neuropsychology|June 11, 2009
Persistent neuropsychological impairment associated with West Nile virus infectionJoseph R Sadek, Steven A Pergam, Jennifer A Harrington, et al.
Nature|July 22, 2014
A shift of thermokarst lakes from carbon sources to sinks during the Holocene epochK M Walter Anthony, S A Zimov, G Grosse, et al.
Pageof 45